Public Health | August 20, 2022
Godrej reveals how to win the war against Malaria through strategic collaboration
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Man lost 54 Kgs in 6 months with MGB procedure
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Subscribe To Our Newsletter & Stay Updated
